Oligodendrocytes derived from human embryonic stem cells for...

Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Method of regulating cell metabolism or physiology

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C424S093700

Reexamination Certificate

active

07579188

ABSTRACT:
This invention provides populations of neural cells bearing markers of glial cells, such as oligodendrocytes and their precursors. The populations are generated by differentiating pluripotent stem cells such as human embryonic stem cells under conditions that promote enrichment of cells with the desired phenotype or functional capability. Various combinations of differentiation factors and mitogens can be used to produce cell populations bearing markers of oligodendrocyte precursor cells. Upon further differentiation form complex processes characteristic of mature oligodendrocytes. The cells are capable of forming myelin sheaths, and can be used therapeutically improve function of the central nervous system.

REFERENCES:
patent: 5654183 (1997-08-01), Anderson et al.
patent: 5750376 (1998-05-01), Weiss et al.
patent: 5753506 (1998-05-01), Johe
patent: 5766948 (1998-06-01), Gage et al.
patent: 5830621 (1998-11-01), Suzuki et al.
patent: 5830651 (1998-11-01), Cauley et al.
patent: 5849553 (1998-12-01), Anderson et al.
patent: 5851832 (1998-12-01), Weiss et al.
patent: 5928947 (1999-07-01), Anderson et al.
patent: 5968829 (1999-10-01), Carpenter
patent: 6040180 (2000-03-01), Johe
patent: 6090622 (2000-07-01), Gearhart et al.
patent: 6200806 (2001-03-01), Thomson
patent: 6235537 (2001-05-01), North et al.
patent: 6238922 (2001-05-01), Uchida
patent: 6245564 (2001-06-01), Goldman et al.
patent: 6887706 (2005-05-01), Zhang et al.
patent: 7285415 (2007-10-01), Keirstead et al.
patent: 2002/0019046 (2002-02-01), Carpenter
patent: 2253078 (1998-10-01), None
patent: WO 97/07200 (1997-02-01), None
patent: WO 97/32608 (1997-02-01), None
patent: WO 98/50526 (1998-11-01), None
patent: WO 99/01159 (1999-01-01), None
patent: WO 99/20741 (1999-04-01), None
patent: WO 00/23571 (2000-04-01), None
patent: WO 01/28342 (2001-04-01), None
patent: WO 01/51610 (2001-07-01), None
patent: WO 01/68815 (2001-09-01), None
patent: WO 01/88104 (2001-11-01), None
patent: WO 01/98463 (2001-12-01), None
Akiyama, et al. “Remyelination of the rat spinal cord by transplantation of indentified bone marrow stromal cells”,J. Neurosci., (2002) vol. 22(15): 6623-6630.
Arsenijevic, et al. “Isolation of multipotent neural precursors residing in the cortex of the adult human brain”,Exp. Neuro., (2001) vol. 170: 48-62.
Bain, et al. “Embryonic stem cells express neuronal properties in vitro”,Developmental Biology, (1995) vol. 168: 342-357.
Barres, et al. “Cell death and control of cell survival in the oligodendrocyte lineage”,Cell, (1992) vol. 70(1): 31-46.
Barres, et al. “A novel role from thyroid hormone, glucocorticoids and retinoic acid in timing oligodendrocyte development”,Development, (1994) vol. 120: 1097-1108.
Billon, et al. “Normal timing of oligodendrocyte development from genetically engineered, lineage-selectable mouse ES cells”,J. Cell Sci., (2002) vol. 115: 3657-3665.
Björklund, et al. “Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model”,PNAS.
Blakemore, et al. “The origin of remyelinating cells in the central nervous system”,J. Neuroimmunology, (1999) vol. 98: 69-76.
Bottenstien. “Growth requirements in vitro of oligodendrocyte cell lines and neonatal rat brain oligodendrocytes”,Proc. Natl. Acad. Sci. USA, (1986) vol. 83(6): 1955-1959.
Brüstle, et al. “In vitro—generated neural precursors participate in mammalian brain development”,Proc. Natl. Acad. Sci. USA, (1997) vol. 94: 14809-14814.
Brüstle, et al. “Embryonic stem cell-derived glial precursors: A source of myelinating transplants”,Science, (1999) vol. 285: 754-756.
Carpenter, et al. “Enrichment of neurons and neural precursors from human embryonic stem cells”,Exp. Neurology, (2001) vol. 172: 383-397.
Carpenter, et al. “Dopaminergic neurons and proliferation-competent precursor cells for treating Parkinson's disease”,Int'l Patent Application PCT/US02/19477.
Chandross, et al. “Tracking oligodendrocytes during development and regeneration”,Microsci. Res. Tech., (2001) vol. 52(6): 766-777.
Chen, et al. “Gene transfer and expression in oligodendrocytes under the control of myelin basic protein transcriptional control region mediated by adeno-associated virus”,Gene Ther., (1998) vol. 5(1): 50-58.
Fraichard, et al. “In vitro differentiation of embryonic stem cells into glial cells and functional neurons”,J. Cell Sci., (1995) vol. 108: 3181-3188.
Freed. “Will embryonic stem cells be a useful source of dopamine neurons for transplant into patients with Parkinson's Disease?”,PNAS, (2002) vol. 99: 1755-1757.
Gottlieb, et al. “An in vitro pathway from embryonic stem cells to neurons and glia”,Cells Tissues Organs, (1999) vol. 165(3-4): 165-172.
Gu, et al. “Selenium is required for normal upregulation of myelin genes in differentiating oligodendrocytes”,J. Neurosci. Res., (1997) vol. 47(6): 626-635.
Guan, et al. “Embryonic stem cell-derived neurogenesis. Retinoic acid induction and lineage selection of neuronal cells”,Cell Tissue Res., (2001) vol. 305(2): 171-176.
Hajihosseini, et al. “Origin of oligodendrocytes within the human spinal cord”,J. Neurosci., (1996) vol. 16(24): 7981-7994.
Hinks, et al. “Depletion of endogenous oligodendrocyte progenitors rather than increased availability of survival factors is a likely explanation for enhanced survival of transplanted oligodendrocyte progenitors in X-irradiated compared to normal CNS”,Neuropath. Appl. Neurobio., (2001) vol. 27: 59-67.
Holland. “Gliomagenesis: Genetic alterations and mouse models”,Nat. Rev. Genet., (2001) vol. 2(2): 120-129.
Holtkamp, et al. “Chronic inflammatory demyelinating polyradiculoneuropathy with histologically proven optic neuritis”,Acta Neuropathol., (2001) vol. 101: 529-531.
Kalman, et al. “Spectrum and classification on inflammatory demyelinating diseases of the central nervous system”,Curr. Neurology and Neurosci. Reports, (2001) vol. 1: 249-256.
Keirstead, et al. “In vivo immunological suppression of spinal cord myelin development”,Brain Res. Bulletin, (1997) vol. 44(6): 727-734.
Keirstead, et al. “Identification of post-mitotic oligodendrocytes incapable of remyelination within the demyelinated adult spinal cord”,J. Neuropath. Exp. Neurology, (1997) vol. 56(11): 1191-1201.
Keirstead, et al. “A quantifiable model of axonal regeneration in the demyelinated adult rat spinal cord”,Exp. Neurol., (1998) vol. 151: 303-313.
Keirstead, et al. “Response of the oligodendrocyte progenitor cell population (defined by NG2 labelling) to demyelination of the adult spinal cord”,GLIA, (1998) vol. 22: 161-170.
Keirstead, et al. “Polysialylated neural cell adhesion molecule-positive CNS precursors generate both oligodendrocytes and schwann cells to remyelinate the CNS after transplantation”,J. Neurosci., (1999) vol. 19(17): 7529-7536.
Keirsted, et al. “Enchanced axonal regeneration following combined demyelination plus schwann cell transplantation therapy in the injured adult spinal cord”,Exp. Neurol., (1999) vol. 159(1): 225-236.
Keirstead. “Stem cell transplantation into the central nervous system and the control of differentiation”,J. Neurosci. Res., (2001) vol. 63: 233-236.
Kuo, et al. “Differentiation of monkey embryonic stem cells into neural lineages”,Biol. Reprod., (2002).
Lee, et al. “Efficient generation of midbrain and hindbrain neurons from mouse embryonic stem cells”,Nature Biotech., (2000) vol. 18: 675-678.
Li, et al. “Generation of purified neural precursors from embryonic stem cells by lineage selection”,Curr. Bio., (1998) vol. 8: 971-974.
Lie, et al. “The adult substantia nigra contains progenitor cells with neurogenic po

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Oligodendrocytes derived from human embryonic stem cells for... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Oligodendrocytes derived from human embryonic stem cells for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligodendrocytes derived from human embryonic stem cells for... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4088731

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.